Stay updated on Pembrolizumab in Triple Negative Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Triple Negative Breast Cancer Clinical Trial page.

Latest updates to the Pembrolizumab in Triple Negative Breast Cancer Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedRevision from v3.2.0 to v3.3.2 appears to be a site-level update with no changes to the study details, eligibility criteria, or outcomes shown on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check28 days agoChange DetectedThe government funding status banner was removed from the page. The study details, eligibility criteria, and related content remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check43 days agoChange DetectedAdded a requirement that participants consent to providing pre- and post-treatment tissue samples for future research. This affects eligibility and subsequent data collection for the study.SummaryDifference0.3%

- Check71 days agoChange Detected- Added a government funding operating-status notice and updated operating details for NIH Clinical Center (high importance). - Updated version from v3.1.0 to v3.2.0 (moderate importance).SummaryDifference2%

- Check79 days agoChange DetectedMajor update: adds Human Breast Cancer topic (MedlinePlus) and bumps revision to v3.1.0; removes older animal cancer topics and marks the version change from v3.0.2 to v3.1.0.SummaryDifference0.5%

- Check93 days agoChange DetectedUpdated from v3.0.1 to v3.0.2; removed the 'Back to Top' element.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Triple Negative Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Triple Negative Breast Cancer Clinical Trial page.